DrugPatentWatch Database Preview
Xeris Company Profile
» See Plans and Pricing
What is the competitive landscape for XERIS, and when can generic versions of XERIS drugs launch?
XERIS has one approved drug.
There is one US patent protecting XERIS drugs.
There are sixteen patent family members on XERIS drugs in thirteen countries.
Summary for Xeris
| International Patents: | 16 |
| US Patents: | 1 |
| Tradenames: | 2 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Xeris
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-004 | Sep 10, 2019 | RX | Yes | Yes | 9,649,364 | Start Trial | Y | Start Trial | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-004 | Sep 10, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-003 | Sep 10, 2019 | RX | Yes | Yes | 9,649,364 | Start Trial | Y | Start Trial | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Xeris Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016196976 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016201248 | Start Trial |
| Canada | 2999404 | Start Trial |
| China | 108135980 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
